Yiannaki E E, Tzioufas A G, Bachmann M, Hantoumi J, Tsikaris V, Sakarellos-Daitsiotis M, Sakarellos C, Moutsopoulos H M
Department of Pathophysiology, National University of Athens, Greece.
Clin Exp Immunol. 1998 Apr;112(1):152-8. doi: 10.1046/j.1365-2249.1998.00558.x.
In a previous study it was shown that La/SSB contains four linear epitopes, p147-154, p291-302, p301-318 and p349-364. The aim of the present study was to investigate the value of the synthetic epitope analogues of the La/SSB autoantigen for the detection of antibodies to La/SSB, in comparison with recombinant La and fragments of this protein. A total of 122 sera with anti-La/SSB activity, from patients with primary Sjögren's syndrome (pSS) or systemic lupus erythematosus (SLE), were tested in various peptide-based assays. In addition, 62 sera from pSS or SLE patients with other autoantibody specificities and 95 sera from healthy individuals were used as controls. The autoantibody specificity was identified by counter immunoelectrophoresis and immunoblot. The peptide-based ELISA assays presented sensitivities ranging from 78% to 88-8% and specificities from 69% to 94-3%. Dot blot assays exhibited sensitivities ranging from 93-6% to 97%, but remarkably lower specificities from 56% to 88%. The most sensitive and specific peptide 349GSGKGKVQFQGKKTKF364 was synthesized and attached on a tetramer sequential oligopeptide carrier SOC4 and used for immunoassay development. Assays based on the recombinant native La protein, the La-C terminal (215 aa), and the N-terminal of La with a mutation at base pair 640 (nine adenines instead of eight) were also developed and compared with the SOC4 peptide-based assay. Of anti-La-positive sera, 88.1% were reactive with both the synthetic peptide SOC4-(349-364aa) and the recombinant La protein. Eighty-three percent of sera were reactive with the La N-terminus and 67.8% of sera were reactive with the La C-terminus. Using sera that were anti-Ro-positive but anti-La-negative, 37% were reactive with the recombinant protein, 26% with the La N-terminus, 33% with the La C-terminus and only 11 % with the synthetic peptide. Our results suggest that the synthetic peptide epitopes exhibit high sensitivity and specificity for the detection of anti-La/ SSB antibodies in ELISA and dot blot techniques. The peptide SOC4-(349-364aa) has the same sensitivity for the detection of anti-La/SSB antibodies as the recombinant protein.
在先前的一项研究中表明,La/SSB包含四个线性表位,即p147 - 154、p291 - 302、p301 - 318和p349 - 364。本研究的目的是,与重组La及其蛋白片段相比,研究La/SSB自身抗原的合成表位类似物在检测抗La/SSB抗体方面的价值。在各种基于肽的检测中,检测了来自原发性干燥综合征(pSS)或系统性红斑狼疮(SLE)患者的总共122份具有抗La/SSB活性的血清。此外,将62份来自具有其他自身抗体特异性的pSS或SLE患者的血清以及95份来自健康个体的血清用作对照。通过对流免疫电泳和免疫印迹鉴定自身抗体特异性。基于肽的ELISA检测的灵敏度范围为78%至88 - 8%,特异性范围为69%至94 - 3%。斑点印迹检测的灵敏度范围为93 - 6%至97%,但特异性显著较低,为56%至88%。合成了最敏感且特异的肽349GSGKGKVQFQGKKTKF364,并将其连接到四聚体顺序寡肽载体SOC4上,用于免疫检测的开发。还开发了基于重组天然La蛋白、La C末端(215个氨基酸)以及在碱基对640处有突变(九个腺嘌呤而非八个)的La N末端的检测,并与基于SOC4肽的检测进行比较。在抗La阳性血清中,88.1%与合成肽SOC4 - (349 - 364aa)和重组La蛋白均有反应。83%的血清与La N末端有反应,67.8%的血清与La C末端有反应。使用抗Ro阳性但抗La阴性的血清,37%与重组蛋白有反应,26%与La N末端有反应,33%与La C末端有反应,而与合成肽有反应的仅为11%。我们的结果表明,合成肽表位在ELISA和斑点印迹技术中对抗La/SSB抗体的检测具有高灵敏度和特异性。肽SOC4 - (349 - 364aa)在检测抗La/SSB抗体方面与重组蛋白具有相同的灵敏度。